期刊
ACTA PHARMACEUTICA SINICA B
卷 9, 期 6, 页码 1193-1203出版社
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2019.06.010
关键词
WS-157; Tyrosine kinase; EGFR inhibitor; Antitumor activity
资金
- National Natural Science Foundation of China [81430085, 81773562, 81703326]
- Open Fund of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China (China) [KF-GN-201902]
- Natural Science Foundation of He'nan Province of China (China) [162300410303]
- Scientific Program of Henan Province (China) [182102310123]
- China Postdoctoral Science Foundation [2015M572123, 2018M630840, 2019T120641]
- Key Research Program of Higher Education of Henan Province (China) [18B350009]
EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors. In the present study, we reported the discovery of WS-157 from our in-house diverse compound library, which was validated to be a potent and selective EGFR-TKI. WS-157 showed excellent inhibitory activities against EGFR (IC50 = 0.81 nmol/L), EGFR([d746)(-)(750]) (IC50 = 1.2 nmol/L) and EGFR([L858R]) (IC50 = 1.1 nmol/L), but was less effective or even inactive against other nine kinases. WS-157 also displayed excellent antiproliferative activities against a panel of human cancer cell lines, and exhibited the ability to reduce colony formation and wound healing the same as gefitinib. We found that WS-157 upon oral administration showed better anti-tumor activity in A431 bearing xenograft mouse models compared to gefitinib. In addition, WS-157 showed better intestinal absorption than gefitinib and had favorable pharmacokinetic properties and microsomal metabolic stability in different species. These studies indicate that WS-157 has strong antitumor activity in vitro and in vivo, and could be used for the development of anti-lung cancer agent targeting EGFR. (C) 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据